Genetic drugs based on nucleic acid biomolecules are a rapidly emerging class of
medicines that directly reprogramme the central dogma of biology to prevent and treat …

Lipid‐based nanoparticles (LBNPs) are currently the most promising vehicles for nucleic
acid drug (NAD) delivery. Although their clinical applications have achieved success, the …

The earliest example of in vivo expression of exogenous mRNA is by direct intramuscular
injection in mice without the aid of a delivery vehicle. The current state of the art for …

The last few years have witnessed a great advance in the development of nonviral systems
for in vivo targeted delivery of nucleic acids. Lipid nanoparticles (LNPs) are the most …

A new era of nanomedicines that involve nucleic acids/gene therapy has been opened after
two decades in 21st century and new types of more efficient drug delivery systems (DDS) …

In the past decade, nucleic acid‐based drugs have emerged as an extremely promising
approach for silencing specific disease‐related genes and targeting undruggable ones …

A new methodology termed selective organ targeting (SORT) was recently developed that
enables controllable delivery of nucleic acids to target tissues. SORT lipid nanoparticles …

Nanotechnology has shown tremendous success in the drug delivery field for more effective
and safer therapy, and has recently enabled the clinical approval of RNA medicine, a new …

Lipid-based nanoparticles (LBNPs) are biocompatible and biodegradable vesicles that are
considered to be one of the most efficient drug delivery platforms. Due to the prominent …

The promise of therapeutic nucleic acids has long been tempered by difficulty in overcoming
biological barriers to their delivery. The past two decades have seen the development of …